North America dominated the Arthralgia Drugs Market with the largest revenue share of 38.42% in 2025, supported by a high prevalence of arthritis-related disorders, advanced healthcare infrastructure, and strong adoption of innovative pain management therapies.
The Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) segment led the market with a 39.87% share in 2025, driven by their widespread use as first-line therapy for managing joint pain and inflammation associated with osteoarthritis, rheumatoid arthritis, and other musculoskeletal disorders
Asia-Pacific is expected to be the fastest-growing region at a CAGR of 7.4% from 2026 to 2033, fueled by a rapidly aging population, improving healthcare access, and increasing diagnosis rates of musculoskeletal disorders across China, India, and Japan.
Corticosteroids are the fastest-growing drug type, projected to register a CAGR of 7.1%, reflecting the surge in use in patients with severe inflammatory joint conditions requiring rapid symptom control.
The Tablets segment dominated the dosage form category with a 48.64% revenue share in 2025, led by their convenience, ease of administration, and widespread patient preference for long-term pain management.